Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

Aqemia SAS. (2/14/22). "Press Release: Aqemia Announces Pilot Study with Janssen to Utilize Aqemia’s Physics-driven Drug Discovery Technology". Antwerp & Paris.

Organisations Organisation Aqemia SAS
  Organisation 2 Janssen Pharmaceutica N.V. (BE)
  Group Johnson & Johnson (JnJ) (Group)
Products Product Launchpad innovation engine (Aqemia)
  Product 2 small-molecule drug
Persons Person Levesque, Maximilien (Aqemia 202210 CEO + Co-Founder)
  Person 2 Martiano, Emmanuelle (Aqemia 202210 COO + Co-Founder)

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum-inspired physics announces it has entered into a pilot study agreement with Janssen.

Through the agreement Aqemia’s unique technology to predict the potency of small molecules for a given target based on physics-based calculations will be applied to selected Janssen datasets.

The agreement aims at building a common understanding of the performance of Aqemia’s technology and how best to apply it in drug discovery projects on different types of target proteins and diseases. It includes an upfront payment from Janssen.

Maximilien Levesque, CEO and co-founder of Aqemia, commented, “We are very happy to start working with Janssen’s teams to apply our unique technology to drug discovery projects”. He added, “This is a great opportunity for us to demonstrate the scalability and repeatability of Aqemia’s recent successes in drug discovery projects.”

About Aqemia

Aqemia is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms fueling a generative artificial intelligence to design novel drug candidates. The disruptive speed and accuracy of our technological platform enables us to scale drug discovery projects just like tech projects.

For more information visit us on or follow us on LinkedIn.


Aqemia contacts:
Maximilien Levesque:
Emmanuelle Martiano:

Record changed: 2024-03-30


Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Aqemia SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top